drugset / Trial / NCT00002225

A Study of Efavirenz in Combination With Stavudine and Didanosine

NCT00002225 ↗

Phase 2 Completed 60 enrolled Dupont Merck
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus didanosine to HIV-infected patients who have never received anti-HIV treatment.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Didanosine Small molecule — —
Subject Efavirenz Other / unclassified — —
Subject Stavudine Other / unclassified — —